A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CHS-006, as Monotherapy and in Combination With Toripalimab, in Participants With Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 22
- 试验地点
- 4
- 主要终点
- Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab
研究概览
简要总结
This phase 1 open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CHS-006 in combination with toripalimab in 2 phases. Phase 1 (Dose Optimization phase) will explore 2 different dose combinations in participants with advanced/metastatic solid tumors (except pancreatic) and Phase 2 (Indication-specific Expansion phase) will use one selected dose in specific tumor types (non-small cell lung cancer-non squamous [NSCLC-NS] and Hepatocellular carcinoma [HCC])
详细描述
The Dose Optimization phase will enroll participants with advanced/metastatic solid tumors (except pancreatic). Up to 20 participants will be randomized into two dosing arms. Two different primary advanced solid tumors have been selected for investigation of antitumor activity in the Indication-specific Expansion phase. Up to 40 participants will be enrolled into each Indication-specific Expansion phase cohort. All participants in both phases will receive CHS-006 in combination with toripalimab intravenously (IV) every 3 weeks (Q3W).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females, ≥18 years old;
- •Histopathologically or cytologically confirmed advanced solid tumor (except pancreatic) with disease progression after at least 1 prior line of standard therapy (Dose Optimization phase);
- •Tumor-specific criteria (Indication-specific Expansion phase):
- •NSCLC-NS (without sensitizing EGFR/ALK/ROS-1/MET mutations) 2nd line plus (2L+): has received and progressed on at least 1 prior chemotherapy regimen. Prior treatment with both anti-PD-1 therapy and platinum-based chemotherapy either concurrently or sequentially are eligible.
- •Hepatocellular carcinoma (HCC) 2L+: has received and progressed on at least 1 prior anticancer regimen. Participants with prior treatment with an anti-PD-1 or PD-L1 agent are eligible.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and expected survival ≥12 weeks;
- •At least 1 measurable lesion per RECIST v1.1;
- •Adequate organ and marrow function
排除标准
- •Current or prior use of systemic anticancer therapy, including but not limited to chemotherapy, immunotherapy, biologic therapy, hormone therapy, and targeted therapy, within 28 days prior to the 1st dose of CHS-006;
- •NSCLC participants with genomic mutations (e.g., EGFR, ALK, ROS-1, MET, etc.) for which FDA-approved targeted therapies are available or require progression on appropriate prior to enrollment;
- •Prior exposure to monoclonal antibodies (mAbs) targeting TIGIT or any of its ligands, including CD155, CD112, or CD113;
- •Major surgery within 28 days prior to the 1st dose of CHS-006 or still recovering from prior surgery;
- •Symptomatic or untreated central nervous system (CNS) metastases;
- •Use of therapeutic immunosuppressive medication within 28 days prior to the 1st planned dose of CHS-006;
- •Receipt of live, attenuated vaccination within 30 days prior to the 1st dose of CHS- 006;
- •History of active autoimmune disease within the past 2 years, with the following exceptions: vitiligo, alopecia, endocrinopathies controlled by hormone replacement therapy, rheumatoid arthritis and other arthropathies that have not required immunosuppression other than nonsteroidal anti-inflammatory agents, celiac disease controlled by diet, or psoriasis controlled with topical medication;
- •Participants with another active solid tumor that has not been curatively treated.
研究组 & 干预措施
Dose Optimization Phase - Arm A
Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
干预措施: CHS-006 (anti-TIGIT) (Drug)
Dose Optimization Phase - Arm A
Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
干预措施: toripalimab (anti-PD-1) (Drug)
Dose Optimization Phase - Arm B
Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
干预措施: CHS-006 (anti-TIGIT) (Drug)
Dose Optimization Phase - Arm B
Advanced solid tumor participants will receive CHS-006 in combination with toripalimab Q3W
干预措施: toripalimab (anti-PD-1) (Drug)
Indication-specific Expansion Phase - Cohort 1 NSCLC-NS
NSCLC-NS participants will receive CHS-006 in combination with toripalimab Q3W
干预措施: CHS-006 (anti-TIGIT) (Drug)
Indication-specific Expansion Phase - Cohort 1 NSCLC-NS
NSCLC-NS participants will receive CHS-006 in combination with toripalimab Q3W
干预措施: toripalimab (anti-PD-1) (Drug)
Indication-specific Expansion Phase - Cohort 2 HCC
HCC participants will receive CHS-006 in combination with toripalimab Q3W
干预措施: CHS-006 (anti-TIGIT) (Drug)
Indication-specific Expansion Phase - Cohort 2 HCC
HCC participants will receive CHS-006 in combination with toripalimab Q3W
干预措施: toripalimab (anti-PD-1) (Drug)
结局指标
主要结局
Assessment of the number of participants with treatment-emergent adverse events (TEAEs) receiving CHS-006 administered in combination with toripalimab
时间窗: Day 1 of study treatment through up to 90 days post last dose of study treatment
Assessed by number of participants with TEAEs assessed by the investigator as per CTCAE v5.0.
次要结局
- Progression-free survival (PFS) using RECIST v1.1 assessed by the investigator(Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study)
- Description of the PK profile of CHS-006 in combination with toripalimab(Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment)
- Disease control rate (DCR) using RECIST v1.1 assessed by the investigator(Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study)
- Immunogenicity of CHS-006 and/or toripalimab(Measured at multiple timepoints from Day 1 of study treatment through up to 90 days post last dose of study treatment)
- Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by the investigator(Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study)
- Duration of response (DoR) using RECIST v1.1 assessed by the investigator(Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study)
- Overall survival (OS) using RECIST v1.1 assessed by the investigator(Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study)
- Time to response (TTR) using RECIST v1.1 assessed by the investigator(Measured at multiple timepoints from Day 1 of study treatment through +/- 7 days at the completion of or premature withdrawal from the study)